Market revenue in 2024 | USD 87.3 million |
Market revenue in 2035 | USD 421.5 million |
Growth rate | 13.2% (CAGR from 2025 to 2035) |
Largest segment | Ozempic (semaglutide) |
Fastest growing segment | Rybelsus (oral semaglutide) |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2035 |
Quantitative units | Revenue in USD million |
Market segmentation | Ozempic (semaglutide), Wegovy (semaglutide), Rybelsus (oral semaglutide) |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to semaglutide market will help companies and investors design strategic landscapes.
Ozempic (semaglutide) was the largest segment with a revenue share of 57.62% in 2024. Horizon Databook has segmented the UAE semaglutide market based on ozempic (semaglutide), wegovy (semaglutide), rybelsus (oral semaglutide) covering the revenue growth of each sub-segment from 2018 to 2035.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE semaglutide market , including forecasts for subscribers. This country databook contains high-level insights into UAE semaglutide market from 2018 to 2035, including revenue numbers, major trends, and company profiles.
No related statistics found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account